22C3位点PD-L1与ki67 EGFR和血液指标相关性研究

doi:10.3969/j.issn.1006-6233.2021.02.012

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1217 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨非小细胞肺癌中程序性死亡配体-1(programmed death receptor ligand-1,PD-L1)表达与ki67、EGFR突变的相关性。方法: 免疫组织化学法检测2018年11月至2019年7月江苏省肿瘤医院121例NSCLC肿瘤组织中PD-L1(22C3)和ki67表达情况,同时采用ARMS法检测相应组织EGFR基因突变状态,流式法检测血清CD3⁺、CD4⁺、CD8⁺T细胞比例,生化发光法检测LDH、CEA、CA199和CY211。采用χ²检验分析PD-L1表达在临床因素中分布差异性,用Spearman检验分析PD-L1表达与EGFR基因、ki67及血液指标的相关性。结果: PD-L1的低表达率为38%(46/121)、高表达率为23.2%(28/121),ki67高表达率为56.4%(57/101),EGFR突变率为41.7%(20/48)。Ⅲ+Ⅳ分期和局部有淋巴结转移的患者PD-L1阳性表达率显著高于Ⅰ+Ⅱ和无淋巴结转移的患者,差异具有统计学意义(χ²＝6.636、7.726,P<0.05)。PD-L1阳性表达率与EGFR突变型、Ki67高表达、CD8⁺细胞数量增高和LDH增高具有显著相关性,呈正相关(P<0.05)。结论: 肺癌患者PD-L1(22C3)表达率高,分期晚、淋巴结转移、ki67高表达、EGFR突变、CD8⁺T细胞数量和LDH增高的患者,PD-L1表达率显著增高,与预后较差的临床指标相关,是筛选Pembrolizumab治疗的指标,也可能成为NSCLC潜在预后标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：非小细胞肺癌, 程序性死亡配体, EGFR基因突变, ki67

Abstract：Objective: To explore the relationship between the expression of programmed death receptor ligand-1(PD-L1) and the mutations of KI67 and EGFR in non-small-cell lung cancer. Methods: The expression of PD-L1(22C3)and Ki67 in 121 NSCLC tissues from November 2018 to July 2019 was detected with immunohistochemistry. The ARMS method was used to detect the mutations of the corresponding tissue EGFR gene, and the flow cytometry method was used to detect the proportion of serum CD3⁺, CD4⁺ and CD8⁺ T cells. The biochemical luminescence method was used to detect LDH, CEA, CA199 and CY211. The χ² analysis was used to analyze the differences in the distribution of PD-L1 expression in clinical factors, and the Spearman test was used to analyze the correlation between PD-L1 expression and EGFR gene, ki67 and blood indicators. Results: The low expression rate of PD-L1 was 38% (46/121), the high expression rate was 23.2% (28/121), the high expression rate of ki67 was 56.4% (57/101), and the EGFR mutation rate was 41.7% (20/48). The positive expression rate of PD-L1 in patients with stage III+IV and local lymph node metastasis was significantly higher than that in patients with I+II and without lymph node metastasis, and the difference was statistically significant (χ²=6.636, 7.726, P<0.05). The positive expression rate of PD-L1 was significantly correlated with EGFR mutants, high ki67 expression, increased number of CD8⁺ cells, and increased LDH, and was positively correlated (P<0.05). Conclusion: The expression rate of PD-L1 (22C3) is high in patients with lung cancer, and the expression rate of PD-L1 is significantly increased in patients with advanced staging, lymph node metastasis, high expression of ki67, EGFR mutation, CD8⁺ T cell number, and LDH. Related to clinical indicators with poor prognosis, it is an indicator for screening Pembrolizumab treatment and may also become a potential prognostic marker for NSCLC.

Key words： NSCLC PD-L1 EGFR Ki67

基金资助:国家自然青年科学基金,(编号:81601843)

通讯作者: 竺明晨

引用本文:

冒学莲, 王承霞, 陈艳, 贾张军, 竺明晨. 22C3位点PD-L1与ki67 EGFR和血液指标相关性研究[J]. 河北医学, 2021, 27(2): 233-237.
MAO Xuelian, WANG Chengxia, CHEN Yan, et al. Study on the Correlation Between PD-L1 at 22C3 Locus and Ki67 EGFR and Blood Indicators. HeBei Med, 2021, 27(2): 233-237.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.02.012 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I2/233

[1] Chakravarti N,V G Prieto. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs:immunohistochemistry analysis[J]. Transl Lung Cancer Res,2015,4(6):743~751.
[2] Zhou G W,Y Xiong S. Chen,et al. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer:A meta-analysis of randomized clinical trials[J]. Medicine (Baltimore),2016,95(35):e4611.
[3] Zak K M ,R Kitel S, Przetocka,et al. Structure of the complex of human programmed death 1,PD-1,and its ligand PD-L1[J]. Structure,2015,23(12):2341~2348.
[4] Lin C,X Chen,M Li,et al. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma[J]. Clin Lung Cancer,2015,16(5):e25~e35.
[5] Koh J, H Go,B Keam,et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma:comparison with histology and driver oncogenic alteration status[J]. Mod Pathol,2015,28(9):1154~1166.
[6] Song S G,J Lee J, Koh,et al. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer[J]. Diagn Cytopathol,2020,48(4):291~299.
[7] Tang Y W,Fang Y, Zhang,et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs[J]. Oncotarget,2015,6(16):14209~14219.
[8] Reck MD, Rodriguez-Abreu A G, Robinson,et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell Lung cancer[J]. N Engl Med,2016,375(19):1823~1833.
[9] Rittmeyer A,F, Barlesi D,Waterkamp,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3,open-label,multicentre randomised controlled trial[J]. Lancet,2017,389(10066):255~265.
[10] Pezzuto A F,Cappuzzo M, D'Arcangelo,et al. Prognostic value of p16 protein in patients with surgically treated non-small cell lung cancer; relationship with Ki-67 and PD-L1[J]. Anticancer Res,2020,40(2):983~990.
[11] Folescu R C M,Levai M L, Grigoras,et al. Expression and significance of Ki-67 in lung cancer[J]. Rom Morphol Embryol,2018,59(1):227~233.
[12] Sun J M ,W Zhou,Y L Choi,et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer:a large cohort study of surgically resected cases[J].Thorac Oncol,2016,11(7):1003~1011.
[13] Madore J,R E Vilain,A M Menzies,et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients:implications for anti-PD-1/PD-L1 clinical trials[J]. Pigment Cell Melanoma Res,2015,28(3):245~253.